These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Bendandi M, Rodríguez-Calvillo M, Inogés S, López-Díaz de Cerio A, Pérez-Simón JA, Rodríguez-Caballero A, García-Montero A, Almeida J, Zabalegui N, Giraldo P, San Miguel J, Orfao A. Leuk Lymphoma; 2006 Jan 01; 47(1):29-37. PubMed ID: 16321824 [Abstract] [Full Text] [Related]
12. Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients. Hobo W, Strobbe L, Maas F, Fredrix H, Greupink-Draaisma A, Esendam B, de Witte T, Preijers F, Levenga H, van Rees B, Raymakers R, Schaap N, Dolstra H. Cancer Immunol Immunother; 2013 Aug 01; 62(8):1381-92. PubMed ID: 23728352 [Abstract] [Full Text] [Related]
15. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Titzer S, Christensen O, Manzke O, Tesch H, Wolf J, Emmerich B, Carsten C, Diehl V, Bohlen H. Br J Haematol; 2000 Mar 01; 108(4):805-16. PubMed ID: 10792287 [Abstract] [Full Text] [Related]
16. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, de Vries IJ, Jongmans W, Adema GJ, Debruyne FM, de Mulder PH, Oosterwijk E, Mulders PF. J Immunother; 2002 Mar 01; 25(6):500-8. PubMed ID: 12439347 [Abstract] [Full Text] [Related]
17. [Induction of active antitumor immune response by myeloma idiotype protein-pulsed dendritic cells]. Yin XR, Zhang M, Luo YY, Lin X, He PC, Chen LM, Cai RB, Guo GL. Ai Zheng; 2005 Jun 01; 24(6):657-62. PubMed ID: 15946473 [Abstract] [Full Text] [Related]
18. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Coscia M, Mariani S, Battaglio S, Di Bello C, Fiore F, Foglietta M, Pileri A, Boccadoro M, Massaia M. Leukemia; 2004 Jan 01; 18(1):139-45. PubMed ID: 14574332 [Abstract] [Full Text] [Related]
19. CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma. Hong S, Qian J, Li H, Yang J, Lu Y, Zheng Y, Yi Q. Cancer Immunol Immunother; 2012 Apr 01; 61(4):561-71. PubMed ID: 22002243 [Abstract] [Full Text] [Related]
20. B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice. Cohen S, Haimovich J, Hollander N. J Immunother; 2005 Apr 01; 28(5):461-6. PubMed ID: 16113602 [Abstract] [Full Text] [Related] Page: [Next] [New Search]